Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Protective drug for D-GaIN/LPS induced liver injury

A liver injury and drug technology, applied in the field of medicine, can solve problems such as large individual differences, inability to develop, and obvious side effects of drugs

Inactive Publication Date: 2019-03-12
HUBEI UNIV FOR NATITIES
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] (1) Clinically commonly used therapeutic drugs such as broad-spectrum antibacterial drugs, glucocorticoids, immunoglobulins, insulin, and coagulation-regulating drugs have large individual differences in drug use, and the side effects of drugs are obvious, so the patient's tolerance and compliance are not good
In addition, the prices of immunoglobulin, insulin, and coagulation-regulating drugs are relatively high, which brings a large economic burden to patients
[0010] (2) Other adjuvant treatment methods such as the type of resuscitation fluid and resuscitation volume are still controversial and have not yet been quantified; blood purification or the effect is not as expected or the side effects are obvious, and the medical cost is relatively high; Professional technicians operate, and cannot be carried out in grassroots and economically backward areas
[0011] (3) The traditional Chinese medicine treatment of sepsis is mostly based on prescriptions and unit medicines, limited by the constraints of traditional Chinese medicine extraction technology, there are few reports on the analysis of monomer compounds, and only preliminary evidence of anti-inflammatory or immune-regulating effects of drugs, and The mechanism has not been further explored
[0013] There are many difficulties in solving the above problems. It is difficult to optimize the efficacy of drugs and reduce adverse drug reactions. The limitations of analysis and development cause safety problems after large-scale use of drugs; non-standard clinical use causes problems in the effectiveness and safety of preparations; The research and development costs of surgical operations such as blood purification are relatively high, there are many technical problems to be solved, and the operation requires the support of professional technicians
Solving the above problems requires huge financial support, which in turn increases the cost of treatment and aggravates the economic burden on patients and society

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Protective drug for D-GaIN/LPS induced liver injury
  • Protective drug for D-GaIN/LPS induced liver injury
  • Protective drug for D-GaIN/LPS induced liver injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0055] In order to make the object, technical solution and advantages of the present invention more clear, the present invention will be further described in detail below in conjunction with the examples. It should be understood that the specific embodiments described here are only used to explain the present invention, not to limit the present invention.

[0056] The mouse model of liver injury induced by galactosamine combined with lipopolysaccharide (D-GaIN / LPS) is commonly used to analyze septic liver injury. At present, there is no report on the analysis of carotenoids in the treatment of sepsis.

[0057] The medicament for protecting D-GaIN / LPS-induced liver damage provided by the embodiments of the present invention uses carotene as an active ingredient.

[0058] The present invention will be further described below in conjunction with specific analysis.

[0059] Such as figure 1 , the animal model construction method provided by the embodiment of the present invent...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medicine and pharmacology and discloses a protective drug for D-GaIN / LPS induced liver injury. The protective drug for induced liver injury is daucosterol. It is indicated herein that daucosterol has anti-inflammatory and immunoregulatory activities; daucosterol may promote generation of CD4+T cells to assist a mouse to resist disseminated candidiasis when used to treat the mouse with disseminated candidiasis; a mouse model with galactosamine lipoxygenase induced liver injury is commonly used to analyze pyemic liver injury; daucosterol is used herein to intervene the mouse model with D-GaIN / LPS induced liver injury, the protective action and possible mechanism of daucosterol against D-GaIN / LPS induced liver injury is explored, and daucosterolis significant to analyze a drug to treat pyemia.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a medicine for protecting liver damage induced by D-GaIN / LPS. Background technique [0002] At present, the existing technologies commonly used in the industry are as follows: [0003] Sepsis is a destructive systemic inflammatory response caused by infection (bacteria, virus, fungus, etc.), which leads to disorders of the body's immune system, coagulation / fibrinolytic system, metabolism, and microcirculation, and can eventually induce multiple organ dysfunction and injury. Clinical syndromes of septic shock. Sepsis is one of the most common critical illnesses in the ICU and has become the third leading cause of death in patients with high morbidity and high mortality. There are an average of more than 18 million cases of severe sepsis every year in the world. In the United States, there are about 700,000 sepsis patients every year, and more than 200,000 patients d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61P1/16A61P29/00A61P31/04
CPCA61K31/704A61P1/16A61P29/00A61P31/04
Inventor 向阳武璐璐吴昊万星袁林李丽丽万昭陈明
Owner HUBEI UNIV FOR NATITIES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products